Free Trial
→ Elon Musk’s $1 Quadrillion AI IPO (From Brownstone Research) (Ad)tc pixel Free IMVT Stock Alerts

Immunovant (IMVT) Financials

Immunovant logo
$31.61 +0.81 (+2.63%)
Closing price 04:00 PM Eastern
Extended Trading
$31.61 0.00 (0.00%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Immunovant

Annual Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -29 -66 -107 -107 -157 -211 -259 -414 -506
Consolidated Net Income / (Loss)		 -29 -66 -107 -107 -157 -211 -259 -414 -506
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -107 -157 -211 -259 -414 -506
Total Pre-Tax Income 		-29 -66 -108 -108 -157 -211 -259 -413 -505
Total Operating Income		 -28 -66 -108 -108 -156 -218 -283 -438 -533
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 28 66 108 108 156 218 283 438 533
Selling, General & Admin Expense		 2.69 18 40 40 54 48 57 77 76
Research & Development Expense		 26 48 69 69 102 170 225 361 457
Total Other Income / (Expense), net		 -0.16 -0.21 0.33 0.33 -0.78 7.33 24 25 28
Interest & Investment Income		 - - - - - 7.58 25 25 25
Other Income / (Expense), net		 -0.16 0.41 0.33 0.33 -0.78 -0.25 -1.01 0.47 2.18
Income Tax Expense		 0.02 0.10 -0.36 -0.36 -0.08 0.01 0.57 0.89 0.22
Basic Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73) ($2.77)
Weighted Average Basic Shares Outstanding		 22.17M 43.20M 87.76M 97.98M 109.68M 123.08M 138.10M 151.57M 182.42M
Diluted Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73) ($2.77)
Weighted Average Diluted Shares Outstanding		 22.17M 43.20M 87.76M 97.98M 109.68M 123.08M 138.10M 151.57M 182.42M
Weighted Average Basic & Diluted Shares Outstanding		 22.17M 43.20M 87.76M 87.76M 116.51M 130.41M 146.05M 170.92M 205.31M

Quarterly Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148
Consolidated Net Income / (Loss)		 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148
Net Income / (Loss) Continuing Operations		 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148
Total Pre-Tax Income 		-58 -52 -75 -87 -109 -111 -106 -120 -126 -109 -151
Total Operating Income		 -62 -62 -81 -94 -116 -114 -114 -127 -132 -114 -160
Total Operating Expenses		 62 62 81 94 116 114 114 127 132 114 160
Selling, General & Admin Expense		 14 13 15 19 18 20 20 26 18 15 17
Research & Development Expense		 48 48 66 75 97 95 94 101 114 99 142
Total Other Income / (Expense), net		 3.59 10 5.79 7.21 6.70 3.33 7.96 7.52 5.85 5.28 8.85
Interest & Investment Income		 3.57 8.93 - 7.18 6.07 4.59 6.89 6.34 5.60 5.33 8.06
Other Income / (Expense), net		 0.02 1.09 -2.59 0.03 0.63 -1.26 1.07 1.19 0.25 -0.05 0.80
Income Tax Expense		 0.45 -0.11 0.23 0.08 0.08 0.15 0.58 0.91 0.59 1.55 -2.84
Basic Earnings per Share		 ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61) ($0.72)
Weighted Average Basic Shares Outstanding		 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M 182.42M
Diluted Earnings per Share		 ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61) ($0.72)
Weighted Average Diluted Shares Outstanding		 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M 182.42M
Weighted Average Basic & Diluted Shares Outstanding		 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M 170.92M 174.32M 175.28M 203.53M 205.31M

Annual Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 6.99 94 300 300 94 -117 259 79 188
Net Cash From Operating Activities		 -29 -53 -83 -83 -106 -188 -214 -376 -407
Net Cash From Continuing Operating Activities		 -29 -53 -83 -83 -106 -188 -214 -376 -407
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -107 -157 -211 -259 -414 -506
Consolidated Net Income / (Loss)		 -29 -66 -107 -107 -157 -211 -259 -414 -506
Depreciation Expense		 0.01 0.02 0.07 0.07 0.13 0.19 0.23 0.38 0.41
Amortization Expense		 - 0.00 - 0.93 - 1.13 1.13 0.13 0.10
Non-Cash Adjustments To Reconcile Net Income		 1.49 8.20 19 19 35 32 41 50 56
Changes in Operating Assets and Liabilities, net		 -1.45 4.81 4.57 4.57 15 -11 2.63 -12 42
Net Cash From Investing Activities		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76 -0.01
Net Cash From Continuing Investing Activities		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76 -0.01
Purchase of Property, Plant & Equipment		 -0.05 -0.03 -0.21 -0.21 -0.25 -0.20 -0.36 -0.76 -0.01
Net Cash From Financing Activities		 36 147 383 383 200 71 472 454 596
Net Cash From Continuing Financing Activities		 36 147 383 383 200 71 472 454 596
Repurchase of Common Equity		 -0.52 -3.11 -1.24 -1.24 0.00 -0.27 -6.01 -0.32 -0.50
Issuance of Common Equity		 20 0.00 386 386 200 71 473 450 544
Other Financing Activities, net		 16 112 1.10 1.10 0.13 0.66 5.69 4.81 52
Effect of Exchange Rate Changes		 - - - - -0.09 0.22 0.99 0.75 -0.30
Cash Income Taxes Paid		 0.07 0.06 0.17 0.17 - 0.00 0.51 1.20 2.39

Quarterly Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -60 421 -56 -75 -87 -98 339 -115 -77 473 -92
Net Cash From Operating Activities		 -60 -47 -60 -76 -89 -100 -111 -117 -103 -92 -95
Net Cash From Continuing Operating Activities		 -60 -47 -60 -76 -89 -100 -111 -117 -103 -92 -95
Net Income / (Loss) Continuing Operations		 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148
Consolidated Net Income / (Loss)		 -59 -51 -75 -87 -109 -111 -106 -121 -127 -111 -148
Depreciation Expense		 0.06 0.06 0.06 0.08 0.09 0.10 0.11 0.11 0.11 0.10 0.10
Amortization Expense		 0.29 0.30 - - 0.02 0.02 0.02 - - 0.03 0.03
Non-Cash Adjustments To Reconcile Net Income		 11 10 8.89 14 13 12 12 19 13 13 11
Changes in Operating Assets and Liabilities, net		 -12 -6.25 5.63 -2.65 7.67 -1.04 -16 -15 11 5.47 42
Net Cash From Investing Activities		 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18 -0.20 0.00 - - -0.01
Net Cash From Continuing Investing Activities		 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18 -0.20 0.00 - - -0.01
Purchase of Property, Plant & Equipment		 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18 -0.20 0.00 - - -0.01
Net Cash From Financing Activities		 0.15 470 1.55 0.69 0.73 2.46 451 2.92 25 565 3.64
Net Cash From Continuing Financing Activities		 0.15 470 1.55 0.69 0.73 2.46 451 2.92 25 565 3.64
Repurchase of Common Equity		 - - - - - - -0.32 - - - 0.08
Other Financing Activities, net		 0.15 3.11 1.55 0.69 0.73 2.46 0.93 2.92 25 21 3.56
Effect of Exchange Rate Changes		 -0.09 -1.61 2.73 0.34 1.05 -0.15 -0.49 -0.57 0.88 0.38 -0.99
Cash Income Taxes Paid		 - - - - - - 0.90 - - 1.64 -0.05

Annual Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 12/31/2018 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 0.41 109 412 412 516 406 666 776 957
Total Current Assets		 0.33 109 409 409 513 404 666 768 949
Cash & Equivalents		 0.33 101 400 400 494 377 635 714 902
Accounts Receivable		 - - 0.60 - 12 0.70 5.34 2.08 1.13
Prepaid Expenses		 0.00 5.46 7.72 8.86 6.25 27 25 51 43
Current Deferred & Refundable Income Taxes		 - 3.05 0.55 - 0.63 0.19 0.17 0.43 2.81
Plant, Property, & Equipment, net		 0.00 0.07 0.20 0.20 0.33 0.33 0.46 0.84 0.44
Total Noncurrent Assets		 0.08 0.25 3.28 3.28 2.30 1.17 0.13 7.72 7.75
Other Noncurrent Operating Assets		 0.08 0.25 3.28 3.28 2.30 1.17 0.13 7.72 7.75
Total Liabilities & Shareholders' Equity		 0.41 109 412 412 516 406 666 776 957
Total Liabilities		 0.38 15 21 21 46 43 49 69 104
Total Current Liabilities		 0.38 15 19 19 45 43 49 69 104
Accounts Payable		 - 4.38 2.43 2.43 19 1.35 7.16 18 7.54
Accrued Expenses		 0.08 11 15 15 25 40 41 51 97
Other Current Liabilities		 - 0.00 1.18 1.18 1.15 1.52 0.15 0.37 0.25
Total Noncurrent Liabilities		 0.00 0.00 2.24 2.24 1.22 0.05 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 94 391 391 470 362 618 707 853
Total Preferred & Common Equity		 0.02 94 391 391 470 362 618 707 853
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 94 391 391 470 362 618 707 853
Common Stock		 0.03 185 590 590 825 928 1,442 1,946 2,597
Retained Earnings		 -0.00 -91 -199 -199 -355 -566 -826 -1,240 -1,745
Accumulated Other Comprehensive Income / (Loss)		 - -0.02 -0.30 -0.30 0.40 0.85 1.91 1.46 0.73

Quarterly Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2022 12/31/2022 6/30/2023 9/30/2023 12/31/2023 6/30/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025
Total Assets		 428 456 351 292 711 590 516 421 661 583 1,052
Total Current Assets		 426 454 350 291 711 589 507 413 652 574 1,043
Cash & Equivalents		 406 433 330 270 691 560 473 375 599 522 995
Accounts Receivable		 3.78 0.70 0.82 1.42 1.03 2.42 1.88 2.22 1.94 1.97 1.64
Prepaid Expenses		 17 21 19 20 19 27 33 36 51 50 47
Plant, Property, & Equipment, net		 0.31 0.36 0.33 0.30 0.38 0.57 0.67 0.75 0.74 0.63 0.53
Total Noncurrent Assets		 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64 8.94 8.78 8.92
Other Noncurrent Operating Assets		 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64 8.94 8.78 8.92
Total Liabilities & Shareholders' Equity		 428 456 351 292 711 590 516 421 661 583 1,052
Total Liabilities		 32 42 51 40 32 45 67 68 53 63 66
Total Current Liabilities		 32 41 51 40 32 45 67 68 53 63 66
Accounts Payable		 7.46 14 26 7.51 3.91 11 21 20 7.84 6.92 8.62
Accrued Expenses		 23 26 24 32 28 34 46 48 45 56 58
Total Noncurrent Liabilities		 0.61 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 396 415 300 252 679 545 449 353 609 520 986
Total Preferred & Common Equity		 396 415 300 252 679 545 449 353 609 520 986
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 396 415 300 252 679 545 449 353 609 520 986
Common Stock		 841 920 940 950 1,430 1,456 1,469 1,483 1,967 2,005 2,582
Retained Earnings		 -444 -507 -640 -699 -750 -913 -1,022 -1,133 -1,360 -1,487 -1,597
Accumulated Other Comprehensive Income / (Loss)		 -1.24 1.38 0.58 0.51 -0.60 1.82 1.91 2.48 1.74 1.45 1.20

Annual Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2019 3/31/2020 3/31/2021 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - 203,532,180.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 203,532,180.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -2.48
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -129.77% -64.10% 0.87% 0.00% -38.62% -30.00% -54.83% -21.28%
EBIT Growth		 0.00% -129.76% -64.15% 0.00% 0.00% -39.36% -29.83% -54.27% -21.26%
NOPAT Growth		 0.00% -132.46% -63.62% 0.00% 0.00% -39.89% -29.52% -54.98% -21.62%
Net Income Growth		 0.00% -132.13% -61.82% 0.00% 0.00% -34.60% -22.93% -59.58% -22.17%
EPS Growth		 0.00% -19.38% 20.78% 0.00% 0.00% -19.58% -9.94% -45.21% -1.47%
Operating Cash Flow Growth		 0.00% -86.91% -56.17% 0.00% 0.00% -77.35% -13.83% -75.46% -8.36%
Free Cash Flow Firm Growth		 0.00% 0.00% -84.94% -2.94% 0.00% 0.00% -19.40% -63.53% -3.85%
Invested Capital Growth		 0.00% -1,451,239.29% -33.28% 0.00% 0.00% 41.49% -25.43% 62.95% -659.01%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -23.71% 31.72% 0.00% 0.00% -6.98% -7.23% -9.50%
EBIT Q/Q Growth		 0.00% 0.00% -23.76% 31.12% 0.00% 0.00% -7.41% -7.17% -9.49%
NOPAT Q/Q Growth		 0.00% 0.00% -24.13% 30.32% 0.00% 0.00% -6.25% -8.13% -9.39%
Net Income Q/Q Growth		 0.00% 0.00% -22.75% 30.64% 0.00% 0.00% -6.53% -8.13% -8.92%
EPS Q/Q Growth		 0.00% 0.00% 31.46% -5.17% 0.00% 0.00% -2.17% -5.00% -3.36%
Operating Cash Flow Q/Q Growth		 0.00% -24.21% -56.17% 26.81% 0.00% -13.81% -1.86% -15.68% 3.68%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 24.92% 0.00% 0.00% 0.00% -16.33% 6.95%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -10.79% 0.00% 0.00% -51.88% 70.44% -490.20%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.07% 100.15% 99.67% 99.67% 99.95% 100.00% 100.22% 100.22% 100.04%
Interest Burden Percent		 100.00% 100.95% 100.00% 100.00% 100.00% 96.53% 91.21% 94.35% 95.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -116,483.38% -141.11% -44.25% -27.44% -33.36% -50.69% -52.91% -62.46% -64.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -116,483.38% -141.11% -44.25% -27.44% -33.36% -50.69% -52.91% -62.46% -64.82%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -70.57% -27.44% 0.00% -33.36% -58.20% -41.98% -58.50% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -76 -109 -153 -198 -307 -373
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -34,806.00% -40.03% -12.68% -7.93% -9.62% -13.37% -12.14% -15.88% -16.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -19.33% - - - -43.35% -43.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -66 -108 -108 -157 -219 -284 -438 -531
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -66 -108 -107 -157 -217 -282 -437 -530
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 4,072.99 9.34 4.01 4.01 1.37 5.57 7.60 4.10 5.93
Price to Tangible Book Value (P/TBV)		 4,072.99 9.34 4.01 4.01 1.37 5.57 7.60 4.10 5.93
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 12.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.07 -1.03 -1.02 -1.05 -1.05 -1.03 -1.02 -1.04
Leverage Ratio		 16.50 1.17 1.07 1.05 1.10 1.11 1.09 1.09 1.11
Compound Leverage Factor		 16.50 1.18 1.07 1.05 1.10 1.07 1.00 1.03 1.06
Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 7.56% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -75.33 32.30 44.48 44.48 7.53 25.30 55.92 22.31 25.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.85 7.12 21.79 21.79 11.52 9.34 13.70 11.16 9.09
Quick Ratio		 0.85 6.57 21.35 21.32 11.37 8.71 13.18 10.41 8.65
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -40 -74 -76 0.00 -163 -194 -318 -330
Operating Cash Flow to CapEx		 -54,898.08% -172,119.35% -39,679.52% -39,679.52% -41,776.38% -95,529.44% -59,507.50% -49,522.27% -5,091,375.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -63.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -85.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -85.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -0.00 -6.50 -8.67 -8.67 -24 -14 -18 -6.52 -50
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -6.50 -2.16 0.00 0.00 9.95 -3.57 11 -43
Enterprise Value (EV)		 100 778 1,171 1,171 148 1,644 4,059 2,189 4,154
Market Capitalization		 100 879 1,571 1,571 641 2,020 4,694 2,903 5,056
Book Value per Share		 $0.00 $1.67 $4.00 $4.00 $4.04 $2.78 $4.25 $4.16 $4.19
Tangible Book Value per Share		 $0.00 $1.67 $4.00 $4.00 $4.04 $2.78 $4.25 $4.16 $4.19
Total Capital		 0.32 94 391 391 470 362 618 707 853
Total Debt		 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.03 -101 -400 -400 -494 -377 -635 -714 -902
Capital Expenditures (CapEx)		 0.05 0.03 0.21 0.21 0.25 0.20 0.36 0.76 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -6.81 -9.91 -9.91 -25 -15 -18 -15 -58
Debt-free Net Working Capital (DFNWC)		 0.24 94 390 390 468 361 617 699 844
Net Working Capital (NWC)		 -0.06 94 390 390 468 361 617 699 844
Net Nonoperating Expense (NNE)		 8.70 20 32 32 48 58 61 107 133
Net Nonoperating Obligations (NNO)		 -0.03 -101 -400 -400 -494 -377 -635 -714 -902
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.07 1.00 0.13 1.32 1.36 0.51 0.51
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73) ($2.77)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 97.98M 97.98M 109.68M 123.08M 138.10M 151.57M 182.42M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) ($1.43) ($1.71) ($1.88) ($2.73) ($2.77)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 97.98M 97.98M 109.68M 123.08M 138.10M 151.57M 182.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.22) ($1.22) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 87.76M 87.76M 116.51M 130.41M 146.05M 170.92M 205.31M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -76 -109 -153 -198 -307 -373
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 -105.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -74.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -105.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -74.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.82% -4.68% -1.15% -1.15% 0.00% -0.13% -2.32% -0.08% -0.10%

Quarterly Metrics And Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 203,532,180.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 203,532,180.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -25.95% 8.56% -30.62% -21.16% -87.21% -92.06% -35.45% -33.72% -14.24% 0.99% -40.85%
EBIT Growth		 -26.54% 8.09% -30.61% -20.82% -86.33% -91.14% -35.09% -33.72% -14.25% 0.99% -40.80%
NOPAT Growth		 -24.56% 3.86% -25.86% -20.14% -87.29% -85.70% -40.74% -34.94% -13.84% -0.05% -40.17%
Net Income Growth		 -22.40% 18.68% -26.73% -17.87% -86.01% -116.12% -41.33% -38.40% -15.93% 0.44% -38.90%
EPS Growth		 -9.76% 26.53% -8.70% -5.26% -64.44% -111.11% -26.00% -18.33% 1.35% 19.74% -14.29%
Operating Cash Flow Growth		 -197.53% -1.52% -7.00% -60.86% -47.60% -113.15% -85.32% -54.08% -15.64% 8.03% 14.08%
Free Cash Flow Firm Growth		 -42.35% -1.40% 0.00% -419.24% -113.97% -40.69% -71.10% -41.22% -51.44% -34.79% 24.31%
Invested Capital Growth		 -80.72% 35.34% -25.43% 49.01% -31.85% -90.36% 62.95% 162.74% 90.94% 61.98% -659.01%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 20.91% 2.16% -38.08% -12.84% -22.20% -0.38% 2.44% -11.82% -4.35% 13.03% -38.80%
EBIT Q/Q Growth		 20.81% 2.14% -38.05% -12.93% -22.13% -0.39% 2.43% -11.78% -4.34% 13.00% -38.75%
NOPAT Q/Q Growth		 21.25% 0.40% -31.40% -16.57% -22.76% 1.25% 0.42% -11.77% -3.57% 13.21% -39.52%
Net Income Q/Q Growth		 20.66% 12.35% -46.48% -15.71% -25.21% -1.84% 4.21% -13.31% -4.88% 12.54% -33.64%
EPS Q/Q Growth		 21.05% 20.00% -38.89% -20.00% -23.33% -2.70% 17.11% -12.70% -2.82% 16.44% -18.03%
Operating Cash Flow Q/Q Growth		 -26.79% 21.58% -26.75% -27.64% -16.34% -13.25% -10.21% -6.12% 12.69% 9.94% -2.96%
Free Cash Flow Firm Q/Q Growth		 -126.15% -40.54% -7.33% -52.22% 6.81% 7.59% -30.52% -25.64% 0.07% 17.75% 26.71%
Invested Capital Q/Q Growth		 39.80% 36.01% -51.88% 12.85% -55.67% 7.62% 70.44% 247.58% -122.49% -287.53% -490.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.78% 99.79% 100.31% 100.09% 100.07% 100.14% 100.55% 100.76% 100.47% 101.42% 98.11%
Interest Burden Percent		 94.22% 85.22% 89.96% 92.38% 94.72% 96.03% 93.89% 94.97% 95.74% 95.34% 94.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -78.84% -44.51% -52.91% -64.54% -92.17% -74.17% -62.46% -77.58% -95.93% -69.35% -64.82%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,684.46% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -78.84% -44.51% -52.91% -64.54% -92.17% -74.17% -62.46% -77.58% -95.93% -69.35% -64.82%
Return on Equity Simple (ROE_SIMPLE)		 -101.37% -35.84% 0.00% -50.04% -71.93% -108.53% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -43 -43 -57 -66 -81 -80 -80 -89 -92 -80 -112
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.56% -1.48% -3.70% -4.75% -7.57% -5.84% -3.97% -5.45% -6.89% -4.47% -4.48%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.34% - - - -22.69% -11.26% -14.63% -17.75% -8.12% -13.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -62 -60 -83 -94 -115 -116 -113 -126 -132 -114 -159
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -60 -83 -94 -115 -115 -113 -126 -131 -114 -159
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 19.92 8.97 7.60 7.08 9.29 10.31 4.10 4.49 5.41 4.52 5.93
Price to Tangible Book Value (P/TBV)		 19.92 8.97 7.60 7.08 9.29 10.31 4.10 4.49 5.41 4.52 5.93
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 221.84 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.03 -1.03 -1.05 -1.06 -1.03 -1.02 -1.01 -1.03 -1.02 -1.04
Leverage Ratio		 1.11 1.07 1.09 1.11 1.15 1.10 1.09 1.08 1.13 1.10 1.11
Compound Leverage Factor		 1.05 0.91 0.98 1.03 1.09 1.05 1.02 1.03 1.09 1.05 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 71.75 113.30 56.91 49.80 35.08 28.24 23.69 28.60 23.39 38.98 27.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.23 22.14 13.70 13.08 7.61 6.04 11.16 12.32 9.07 15.74 9.09
Quick Ratio		 6.74 21.56 13.18 12.49 7.12 5.52 10.41 11.36 8.28 15.03 8.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -35 -49 -53 -81 -75 -70 -91 -114 -114 -94 -69
Operating Cash Flow to CapEx		 -176,647.06% -35,952.67% -39,799.33% -41,867.58% -45,228.06% -55,772.78% -55,043.28% 0.00% 0.00% 0.00% -1,188,237.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -18 -12 -18 -15 -24 -22 -6.52 9.63 -2.17 -8.39 -50
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.09 6.34 -3.57 15 -5.77 -10 11 25 22 14 -43
Enterprise Value (EV)		 4,747 5,404 4,059 3,296 3,700 3,261 2,189 2,136 2,288 3,461 4,154
Market Capitalization		 5,016 6,095 4,694 3,856 4,173 3,636 2,903 2,735 2,810 4,456 5,056
Book Value per Share		 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40 $4.16 $3.56 $2.98 $5.63 $4.19
Tangible Book Value per Share		 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40 $4.16 $3.56 $2.98 $5.63 $4.19
Total Capital		 252 679 618 545 449 353 707 609 520 986 853
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -270 -691 -635 -560 -473 -375 -714 -599 -522 -995 -902
Capital Expenditures (CapEx)		 0.03 0.13 0.15 0.18 0.20 0.18 0.20 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -12 -18 -16 -32 -30 -15 -0.05 -12 -18 -58
Debt-free Net Working Capital (DFNWC)		 251 679 617 544 441 344 699 599 510 977 844
Net Working Capital (NWC)		 251 679 617 544 441 344 699 599 510 977 844
Net Nonoperating Expense (NNE)		 15 8.33 19 21 28 31 27 32 34 31 36
Net Nonoperating Obligations (NNO)		 -270 -691 -635 -560 -473 -375 -714 -599 -522 -995 -902
Total Depreciation and Amortization (D&A)		 0.35 0.35 0.06 0.15 0.11 0.12 0.13 0.11 0.11 0.13 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61) ($0.72)
Adjusted Weighted Average Basic Shares Outstanding		 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M 182.42M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76) ($0.63) ($0.71) ($0.73) ($0.61) ($0.72)
Adjusted Weighted Average Diluted Shares Outstanding		 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M 151.57M 170.87M 173.64M 181.51M 182.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M 170.92M 174.32M 175.28M 203.53M 205.31M
Normalized Net Operating Profit after Tax (NOPAT)		 -43 -43 -57 -66 -81 -80 -80 -89 -92 -80 -112
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -2.47% -2.32% 0.00% 0.00% 0.00% -0.08% 0.00% 0.00% -0.20% -0.10%

Financials Breakdown Chart

Key Financial Trends

Immunovant’s latest quarter shows a company still in heavy development mode, with no revenue and large operating losses, but also a very strong cash position after a major financing event. For retail investors, the key takeaway is that IMVT is funding clinical and R&D work with a sizable balance sheet, while burning substantial cash each quarter.

  • Cash remains ample: cash and equivalents rose to $994.5 million in Q3 2026, up from $521.9 million in Q2 2026 and $374.7 million in Q3 2025.
  • Balance sheet got much stronger: total equity increased to $986.1 million in Q3 2026 from $519.7 million in Q2 2026.
  • Recent financing added major liquidity: Q4 2025 cash flow shows $450.0 million from issuance of common equity, helping boost cash substantially.
  • Interest income is meaningful: Q4 2026 interest and investment income was $8.1 million, which helps offset losses at the margin.
  • Operating leverage may improve if spending slows: R&D expense fell to $142.3 million in Q4 2026 from $114.2 million in Q2 2026 but remained the main driver of costs, suggesting management is still prioritizing pipeline development.
  • No revenue yet: revenue was $0 in every period provided, so the company is still entirely dependent on financing and investment income.
  • Share count has climbed: weighted average basic shares rose to 182.4 million in Q4 2026 from 151.6 million in Q4 2025, indicating dilution.
  • Current assets far exceed current liabilities: in Q3 2026, current assets were $1.04 billion versus current liabilities of $66.3 million, which points to strong near-term liquidity.
  • Losses remain very large: Q4 2026 net loss was $147.9 million, compared with $126.5 million in Q2 2026 and $106.4 million in Q4 2025.
  • Cash burn is persistent: Q4 2026 operating cash flow was negative $95.1 million, after negative $102.5 million in Q2 2026 and negative $110.6 million in Q4 2025.
  • Quarterly losses have generally widened over time: operating expenses climbed to $159.6 million in Q4 2026 from $113.8 million in Q4 2025, reflecting a heavier cost structure.
  • Still no sign of commercial traction: with zero revenue and recurring losses, the investment case remains highly dependent on clinical progress and future financing success.

Bottom line: Immunovant is financially well capitalized for now, and its cash balance gives it runway to keep advancing its pipeline. But the business is still pre-revenue, burn remains high, and dilution has already been significant. For investors, the story is less about current profitability and more about whether upcoming clinical milestones can justify the cash burn and valuation.

06/09/26 11:05 PM ETAI Generated. May Contain Errors.

Immunovant Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Immunovant's fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

Immunovant's net income appears to be on an upward trend, with a most recent value of -$505.61 million in 2026, rising from -$28.60 million in 2018. The previous period was -$413.84 million in 2025. Find out what analysts predict for Immunovant in the coming months.

Immunovant's total operating income in 2026 was -$532.90 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $532.90 million

Over the last 8 years, Immunovant's total revenue changed from $0.00 in 2018 to $0.00 in 2026, a change of 0.0%.

Immunovant's total liabilities were at $104.42 million at the end of 2026, a 51.8% increase from 2025, and a 27,347.1% increase since 2018.

In the past 8 years, Immunovant's cash and equivalents has ranged from $325 thousand in 2018 to $902.11 million in 2026, and is currently $902.11 million as of their latest financial filing in 2026.

Over the last 8 years, Immunovant's book value per share changed from 0.00 in 2018 to 4.19 in 2026, a change of 380,718.2%.


Related Companies

Financial statements for NASDAQ:IMVT last updated on 5/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel